» Articles » PMID: 39857049

Cardiac Markers in Pediatric Laboratory Medicine: Critical Review

Overview
Date 2025 Jan 25
PMID 39857049
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, there are no validated guidelines or recommendations for how to interpret cardiac biomarkers in the pediatric population. The most commonly used cardiac biomarkers are cardiac troponins and natriuretic peptides, but the clinical value of common cardiac biomarkers in pediatric laboratory medicine is restricted due to age- and sex-specific interpretations, and there are no standardized cut-off values. The results from the studies on reference values, as well as results from clinical studies, are difficult to compare with identical studies due to the heterogeneity of subject characteristics (gestational and chronological age, sex, pubertal status, menstrual cycle, exercise), assay characteristics (type of assay, generation of assay, analytical platform used), and experimental protocol characteristics (prospective or retrospective studies, reference population selection, patient population selection, inclusion and exclusion criteria, number of subjects). Future studies need to establish evidence-based cut-offs for specific indications to optimize utilization and standardize the interpretation of common cardiac biomarkers in neonates, children, and adolescents. The aim of this article was to summarize the current analytical and clinical limitations of cardiac troponins and natriuretic peptides in the pediatric population, as informed by the existing published literature.

References
1.
Lam E, Higgins V, Zhang L, Chan M, Bohn M, Trajcevski K . Normative Values of High-Sensitivity Cardiac Troponin T and N-Terminal pro-B-Type Natriuretic Peptide in Children and Adolescents: A Study from the CALIPER Cohort. J Appl Lab Med. 2020; 6(2):344-353. DOI: 10.1093/jalm/jfaa090. View

2.
Correale M, Nunno L, Ieva R, Rinaldi M, Maffei G, Magaldi R . Troponin in newborns and pediatric patients. Cardiovasc Hematol Agents Med Chem. 2009; 7(4):270-8. DOI: 10.2174/187152509789541927. View

3.
Poldervaart J, Rottger E, Dekker M, Zuithoff N, Verheggen P, de Vrey E . No Added Value of Novel Biomarkers in the Diagnostic Assessment of Patients Suspected of Acute Coronary Syndrome. PLoS One. 2015; 10(7):e0132000. PMC: 4503345. DOI: 10.1371/journal.pone.0132000. View

4.
Tilea I, Varga A, Serban R . Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges. Diagnostics (Basel). 2021; 11(5). PMC: 8156776. DOI: 10.3390/diagnostics11050881. View

5.
Cirer-Sastre R, Legaz-Arrese A, Corbi F, George K, Nie J, Carranza-Garcia L . Cardiac Biomarker Release After Exercise in Healthy Children and Adolescents: A Systematic Review and Meta-Analysis. Pediatr Exerc Sci. 2018; 31(1):28-36. DOI: 10.1123/pes.2018-0058. View